Citrate synthase variants improve yield of acetyl-CoA derived 3-hydroxybutyrate in Escherichia coli
Microbial Cell Factories · 12.06.2024 · 23 (1)
DOI: 10.1186/s12934-024-02444-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Microbial Cell Factories, online erschienen am 12.06.2024. Verfasst von Hemshikha Rajpurohit und 1 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical, Materials and Biomedical Engineering, Athens, GA, USA. Hauptthemen laut MEDLINE: Escherichia coli, Acetyl Coenzyme A, Citrate (si)-Synthase, 3-Hydroxybutyric Acid. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science Foundation.
Abstract (Originalsprache)
Background
The microbial chiral product (R)-3-hydroxybutyrate (3-HB) is a gateway to several industrial and medical compounds. Acetyl-CoA is the key precursor for 3-HB, and several native pathways compete with 3-HB production. The principal competing pathway in wild-type Escherichia coli for acetyl-CoA is mediated by citrate synthase (coded by gltA ), which directs over 60% of the acetyl-CoA into the tricarboxylic acid cycle. Eliminating citrate synthase activity (deletion of gltA ) prevents growth on glucose as the sole carbon source. In this study, an alternative approach is used to generate an increased yield of 3-HB: citrate synthase activity is reduced but not eliminated by targeted substitutions in the chromosomally expressed enzyme.
Results
Five E. coli GltA variants were examined for 3-HB production via heterologous overexpression of a thiolase ( phaA ) and NADPH-dependent acetoacetyl-CoA reductase ( phaB ) from Cupriavidus necator . In shake flask studies, four variants showed nearly 5-fold greater 3-HB yield compared to the wild-type, although pyruvate accumulated. Overexpression of either native thioesterases TesB or YciA eliminated pyruvate formation, but diverted acetyl-CoA towards acetate formation. Overexpression of pantothenate kinase similarly decreased pyruvate formation but did not improve 3-HB yield. Controlled batch studies at the 1.25 L scale demonstrated that the GltA[A267T] variant produced the greatest 3-HB titer of 4.9 g/L with a yield of 0.17 g/g. In a phosphate-starved repeated batch process, E. coli ldhA poxB pta-ackA gltA :: gltA [A267T] generated 15.9 g/L 3-HB (effective concentration of 21.3 g/L with dilution) with yield of 0.16 g/g from glucose as the sole carbon source.
Conclusions
This study demonstrates that GltA variants offer a means to affect the generation of acetyl-CoA derived products. This approach should benefit a wide range of acetyl-CoA derived biochemical products in E. coli and other microbes. Enhancing substrate affinity of the introduced pathway genes like thiolase towards acetyl-CoA will likely further increase the flux towards 3-HB while reducing pyruvate and acetate accumulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemical, Materials and Biomedical Engineering, Athens, GA, USA.
- School of Chemical, Materials and Biomedical Engineering, Athens, GA, USA. eiteman@engr.uga.edu.
- Department of Microbiology, University of Georgia, Athens, GA, 30602, USA. eiteman@engr.uga.edu.
Förderung
- National Science Foundation
Zitieren
APA
Rajpurohit, H., & Eiteman, M. A. (2024). Citrate synthase variants improve yield of acetyl-CoA derived 3-hydroxybutyrate in Escherichia coli. Microbial Cell Factories, 23(1). https://doi.org/10.1186/s12934-024-02444-8
Vancouver
Rajpurohit H, Eiteman MA. Citrate synthase variants improve yield of acetyl-CoA derived 3-hydroxybutyrate in Escherichia coli. Microbial Cell Factories. 2024;23(1). doi:10.1186/s12934-024-02444-8
BibTeX
@article{Rajpurohit2024,
author = {Rajpurohit, Hemshikha and Eiteman, Mark A},
title = {Citrate synthase variants improve yield of acetyl-CoA derived 3-hydroxybutyrate in Escherichia coli},
journal = {Microbial Cell Factories},
year = {2024},
volume = {23},
number = {1},
doi = {10.1186/s12934-024-02444-8}
}
EUVIMED